Acetyl cysteine
Phase 3Small molecule
Acetyl cysteine is one of 8 small molecule programs targeting Ototoxicity. It is currently in Phase 3.
2
Indications
7
Total Trials
2
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
5 competitors in Ototoxicity
#DrugCompanyPhaseTrials
1Qualaquin
Sun Pharmaceutical Industries, Inc.Approved
Acetyl cysteine
TTanta University
Phase 3
Bayer Aspirin
BayerPreclinical
SPF Control
BayerPreclinical
BAY987517
BayerPreclinical
Sunscreen Lotion (y65-110)
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pneumonia1 trial
NAC1 trial
Effect of High-Dose NAC on Patients With DPN
Unknown status·—·Phase 4·NCT04766450·30 enrolled
Psoriasis Vulgaris1 trial
Using Acetylcysteine and Vitamin E With Psoriasis Vulgaris
Unknown status·—·Phase 3·NCT05906498·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Acetyl cysteine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTanta University